Citryll Doses First Patient in Phase IIa “Citydream” Trial of CIT-013 for Rheumatoid Arthritis

Citryll Doses First Patient in Phase IIa “Citydream” Trial of CIT-013 for Rheumatoid Arthritis

By, Admin 4 September 2025

Citryll, a biotech company focused on immune-mediated inflammatory diseases, has dosed the first patient in its phase IIa clinical trial “Citydream”. The study will evaluate CIT-013, a first-in-class monoclonal antibody targeting Neutrophil Extracellular Traps (NETs), in patients with moderately active rheumatoid arthritis (RA).

Why This Matters

  • Rheumatoid arthritis (RA): A chronic autoimmune disease marked by joint inflammation, stiffness, and swelling.
  • Unmet need: Despite treatment advances, many patients fail to maintain adequate disease control.
  • Novel approach: CIT-013 clears existing NETs and blocks new formation, offering a dual mechanism distinct from current therapies.

Trial Design – Citydream

  • Type: Phase IIa, randomized, double-blind, placebo-controlled, multi-centre study.
  • Participants: 88 RA patients with moderately active disease.
  • Duration: 6-week treatment phase + open-label extension to further assess safety and efficacy.
  • Location: Conducted across several European sites.

Expert Commentary

Dr. Maarten Kraan, Chief Medical Officer, Citryll:

“Dosing the first patient marks a major milestone. Citydream validates the potential of CIT-013 to transform RA treatment and address unmet needs.”

Dr. Rogier Thurlings, Lead Investigator, Citydream:

“By targeting NETs, CIT-013 offers a disease-modifying approach. Its mode of action differs fundamentally from existing RA therapies, which often fall short.”

Strategic Updates

  • Clinical Advisory Board: Established to guide CIT-013’s RA and autoimmune pipeline development.
  • Pipeline expansion: A second phase IIa trial in hidradenitis suppurativa (HS) is planned for later this year.
  • Funding: Backed by an €85M Series B and strong investor syndicate.
  • Previous success: Phase I trial showed repeat dosing feasibility and safety in RA patients.

About CIT-013

  • First-in-class antibody targeting NETs, a key driver of inflammation in RA and other autoimmune conditions.
  • Dual mechanism:
    - Enhances clearance of existing NETs.
    - Inhibits formation of new NETs.
  • Selectivity: Highly specific for its epitope, minimizing off-target effects.
  • Potential impact: Moves beyond pathway management toward a transformative, disease-modifying strategy.

About Citryll

Citryll is a research-driven biotech pioneering therapies against NETs. The company aims to reshape treatment for RA and other immune-mediated diseases by addressing a fundamental driver of inflammation that has yet to be targeted therapeutically.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!